Drug Profile

QRX 003

Alternative Names: QRX-003; QYLEKI

Latest Information Update: 16 Oct 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Quoin Pharmaceuticals
Class Skin disorder therapies; Small molecules
Mechanism of Action Serine protease inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Netherton Syndrome; Peeling skin syndrome
New Molecular Entity Yes

Highest Development Phases

Phase II/III Netherton Syndrome
Phase I Peeling skin syndrome
Preclinical Ichthyosis; Inborn genetic disorders

Most Recent Events

14 Oct 2026 QRX 003 receives Orphan Drug status for Peeling skin syndrome in European Union
22 Sep 2026 QRX 003 receives Fast track status from the US FDA for Peeling skin syndrome
08 Sep 2026 QRX 003 receives Rare Paediatric Disease Designation for Peeling skin syndrome in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com